Pot Stocks Gearing Up For Strong 2018 As Cannabis CBD Frenzy Intensifies

FLORIDA:  The hemp, cannabis and marijuana industry is booming while more and more retail investors are really taking notice. According to Cowen & Co., legal marijuana sales in the U.S. have the opportunity to reach $50 billion annually by 2026, with cannabis research firm ArcView projecting compound annual growth of 26% in North America through 2021.

The cannabidiol (CBD) market alone is estimated to grow by 700% by 2020, according to Forbes. A new report by market intelligence firm Hemp Business Journal projects that the CBD market will grow to $2.1 billion by 2020, an astronomical jump in value compared to last year’s CBD market of $202 million. Plenty of market professionals firmly believe not many other industries and sectors are growing as quickly as legal marijuana heading into the new year. 

Top Three Best Performing Cannabis Stocks Over The Past Year

CALIFORNIA: SECFilings.com, a financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering the top three best performing stock of the past year. Companies discussed are AXIM Biotechnologies (OTCQB: AXIM), Supreme Pharmaceuticals, and American Cannabis.

#1: AXIM Biotech (+2,445.61%)

AXIM Biotechnologies Inc. (OTCQB: AXIM) is focused on developing a portfolio of over 20 cannabinoid-based pharmaceuticals and nutraceuticals along with 17 patents and 20 trademarks. The company’s flagship products utilize its proprietary chewing gum-based delivery system to provide consumers with superior bioavailability without the negative side effects or stigma of smoking cannabis or taking consuming edibles.

In recent months, the company began early-stage clinical trials of its CanChew Plus for the treatment of irritable bowel syndrome (“IBS”), as well as CanChew Rx for treatment of pain and spasticity in Multiple Sclerosis (MS) patients which is projected to reach a market size of $20 billion by 2024. In addition to those programs, AXIM recently announced a partnership with a US API company to develop an alternative generic version of FDA-approved Marinol® as reported by Forbes. These clinical programs represent multi-billion dollar markets where cannabinoids could prove beneficial in providing patients with much-needed relief.

#2: Supreme Pharmaceuticals (+286.44%)

Supreme Pharmaceuticals Inc. is a one of about 40 licensed producers of medical marijuana under Health Canada’s Access to Cannabis for Medical Purposes Regulations — or ACMPR. The company’s 7-acre — 342,000 square foot — hybrid greenhouse combines the best practices of indoor cultivation with the cost structure of a greenhouse to produce high-quality marijuana at a low cost.

Unlike many other licensed producers, the company is focusing exclusively on the business-to-business market where it will employ a wholesale business model. The company anticipates that the greenhouse will be capable of producing over 50 million grams of cannabis per year at full capacity. Its next buildout will bring on an additional 80,000 square feet of production space in addition to the 40,000 square feet that’s already operational.

#3: American Cannabis (+173.5%)

American Cannabis Co. is a business-to-business consulting firm and distributor of ancillary products and services to the cannabis industry. The company offers turnkey end-to-end solutions to existing and aspiring businesses in the cannabis industry by leveraging its hands-on experience and knowledge to provide business planning, license procurement, and operational best practices.

Recently, the company announced that it secured its first retainer client in the State of Louisiana. CB Medical LLC engaged the company’s services as an applicant of the LSU-sponsored medical marijuana program. The two companies aim to design and operate a medical marijuana program for patients in Louisiana in partnership with the state’s leading university — complete with an indoor cultivation center and laboratory.

Please follow the link to read the full article: http://analysis.secfilings.com/articles/164-top-3-best-performing-cannabis-stocks

Cannabis Industry Expects to Become the Next Biggest Market

NEW YORK: After historical elections earlier this month, other states may be reconsidering their stance on legalization of Cannabis for medical or recreational use. Currently, there are gaps among states concerning cannabis legalization reform and the difficulties for both the government and the businesses involved as 20 percent of Americans can now lawfully use Cannabis.

The largest recreational usage of cannabis is now the state of California. According to Gallup polls, public support for legalizing cannabis has reached 60%, its highest level in Gallup’s 47-year trend. The market for both recreational and medicinal cannabis is projected to grow to $22 billion by 2020 according to ArcView Market Research.

 

Merrill Lynch Is Bullish On Marijuana

NEW YORK: The investment arm of Bank of America, Merrill Lynch, sent out a 45 page equity report last week focused on prospects related to marijuana.

Carefully researched, it was an interesting peek at how heavy hitters on Wall Street are starting to view the expanding industry. The document is not publicly available. It was leaked to this writer by an individual who received the report as a member and investor.

Among the pages were extensive, basic information about cannabis and the cannabinoids THC and CBD. There was also a comprehensive outline on the patchwork of state medical cannabis laws. Further within the document there was an overview of the benefits for a long list of medical conditions, some public polling and then tantalizing information about publicly traded companies already operating in the sphere.

Buying Legal-Marijuana Stocks: Just Say No?

DISTRICT OF COLUMBIA:  Marijuana legalization in multiple states has ushered in a variety of companies and funds that are selling shares.

But should you invest?

Marijuana-related securities have arrived in the form of over-the-counter or penny stocks and special funds for accredited or high-net-worth investors. Some investors have been playing this market for several years already.

But while marijuana has been legalized for medical and recreational use in a short list of states, at the federal level marijuana is still illegal.

Delusional Confidence? A Report From The Marijuana Investor Summit

COLORADO: “When we want to raise capital,” Dooma Wendschuh, the thirty-eight-year-old co-founder of a cannabis company called ebbu, said, “I go up to someone and say, ‘Would you like to invest in my company? Here’s how it will work. One: you may go to prison for making this investment. Two: I may go to prison, and you might lose all your money. Three: our minimum investment is two hundred and fifty thousand dollars. Sure you want to play ball?’ ”

There was nervous laughter from the crowd. It was the first day of the first Marijuana Investor Summit, in Denver, and Wendschuh was speaking at one of the most popular panels, “Raising Funds.” More than eight hundred people from around the country had come to the summit, at the Crowne Plaza Hotel, near the airport. It was a testosterone-fuelled crowd, mostly white men in suits—entrepreneurs mixing with hedge-fund managers and venture capitalists. But there were outliers: an Orthodox Jew with a long white beard, whose family in Philadelphia wants to obtain the first license to grow medical marijuana in Pennsylvania; an African-American man who spent seventeen years on Wall Street, then left to grow pot near Detroit; and a female doctor who wants to start a practice treating chronic conditions with cannabis.

All were convinced that the ongoing legalization of marijuana has created an opportunity for people with a high tolerance for risk to make a killing. Twenty-three states and the District of Columbia have legalized medical marijuana, and four of those—Colorado, Washington, Oregon, and Alaska—have made recreational pot legal. But it’s not legal federally, resulting in chaos and conflicting rules.

MJX Marijuana Index To Feature NYSE Distribution With 3 Unique Tickers

CALIFORNIA: MJX Marijuana Index has been acquired by MJX Ventures, through a new partnership with Interactive Data, a global leader in asset valuations, data, and index management.  According to press releases, MJX Marijuana Index will now feature three unique NYSE tickers with distribution on NYSE’s index system.

Combined with robust third-party data feeds provided by Interactive Data Corporation (IDC), including monthly adjustments for corporate actions and balancing of constituents, MJX Ventures is pleased to be entrenched as the leader in marijuana equities. NYSE distribution for the three MJX Marijuana Index tiers will provide a global platform as MJX’s “best-in-class” system is enhanced and launched in new global markets.

Significant capital and resources are being invested into the MJX infrastructure in order to build the first bona-fide stock index for the sector and a team of broadly experienced securities professionals are now aligned with the Index. Originally founded in Q1 of 2013, the MJX Marijuana Index was built with the vision to establish various funds and ETFs which would track the emerging industry. The overwhelming interest in the index has caused MJX to seek additional partners and expanded distribution to ultimately deliver the best User Experience and data delivery possible.

MJX is taking the following steps to improve the Index experience:

1) MJX is expanding the site to include three indexes: United States Reporting Companies, Non-United States Companies (solely Canadian issuers at this point) and Non-Reporting (pink sheet) Companies; MJX intends to cover every qualified cannabis stock traded throughout the world on these three platforms. This expansion is expected to be completed by September of 2014.

2) Once this expansion is completed, the United States Reporting Company Index will be quoted on the New York Stock Exchange (see below on trading in the Index). MJX may seek listing on NASDAQ’s system in 2015.

Growlife Halted; Marijuana Penny Stocks Doomed

NEW YORK:  I warned you. Over and over, frankly, and consider this yet another warning. Stay away from hyped-up penny stocks, which so far this year has meant specifically staying away from the marijuana-weed-pot penny stocks, most of which even at this moment, are still up many hundreds of percent in the last year. Most of these over-the-counter weed penny stocks are just vehicles for their insiders to sell shares to retail investors caught up in the hype of the legalized marijuana revolution.

Let me explain again. I’ve repeatedly highlighted Growlife PHOT  as a poster-child for this game in which the retail investor is always the mark, and late last week, holders of PHOT woke up to news that the SEC had finally gotten off their butt and was suspending trading in this stock while they investigate the company’s stock trades “because of questions that have been raised about the accuracy and adequacy of information in the marketplace and potentially manipulative transactions in PHOT’s common stock.”

I have certainly been one of those who have raised questions about the accuracy and adequacy and potentially manipulative transactions in PHOT’s common stock. I’m glad to see the investigation, even coming way too late for all those retail investors who got stuck with this now suspended stock.

 

Bloom Off Of Pot Stocks On Wall Street

NEW YORK: Wall Street seems to be losing its appetite for pot.

Marijuana stocks were high flyers — so to speak — after Colorado and Washington states legalized pot sales and several other states announced they may legalize sales or decriminalize possession. Shares in about 20 marijuana-related companies began soaring, with some gaining more than 500% off 52-week lows.

But marijuana mania continues to fade as investors realize there’s more smoke than fire at many companies, which show “pot-tential” but little actual revenue. CannaVest, which specializes in industrial hemp production, had climbed to $180 a share last month. After dropping 11% to to $61.45 Thursday, it’s lost nearly two-thirds of its market value.

The First Pot Stock Billionaire Says His Penny Stock Could Be A Little High

NEVADA:  You have probably never heard of Bart Mackay, a 57-year-old Las Vegas lawyer who works on various ventures like Dot Vegas, which operates the .Vegas top-level domain. But on paper, Mackay is the first pot stock billionaire.

Mackay’s holdings in CannaVest, which bills itself as the world’s leading hemp-based investment company, are valued at $1.8 billion. That figure might seem like a drug-induced hallucination, but it’s technically true. CannaVest is the top-performing stock in America in 2014 with a market capitalization greater than $1 billion. [Read more…]